Gedatolisib联合哌柏西利和内分泌治疗激素受体阳性、HER2阴性晚期乳腺癌女性:开放标签1b期研究剂量扩展组结果
本多中心开放标签1b期研究纳入103例激素受体阳性、HER2阴性晚期乳腺癌女性,评估Gedatolisib联合哌柏西利和内分泌治疗的疗效与安全性。一线组客观缓解率为85.2%,二线及以上组为25.0%-61.5%,最常见3-4级不良事件为中性粒细胞减少(63%)。
要点
- 一线组客观缓解率85.2%(90% CI 69.2-94.8),二线及以上组为25.0%-61.5%。
- 最常见3-4级治疗相关不良事件为中性粒细胞减少63%、口腔炎27%、皮疹20%。
- 3-4级高血糖发生率6%,治疗相关严重不良事件22%,无治疗相关死亡。
核心结论
- Gedatolisib联合哌柏西利和内分泌治疗较已发表的标准治疗结果显示出有前景的客观缓解率,且安全性可接受。
研究设计与样本
- 多中心、开放标签、1b期研究,从美国17个中心招募至少18岁女性患者。
- 剂量扩展部分纳入103例激素受体阳性、HER2阴性晚期乳腺癌且ECOG体能状态0-1的女性,分A-D四组。
- A组为晚期一线初治,B组为内分泌治疗1-2线进展但未用过CDK4/6抑制剂,C和D组为二线及以上且既往用过CDK4/6抑制剂。
- Gedatolisib 180 mg静脉给药,A-C组每周一次、28天为一周期,D组于第1、8、15天给药;来曲唑(A组)、氟维司群(B-D组)和哌柏西利(所有组)按标准剂量和方案给药。
- 主要终点为研究者按RECIST 1.1评估的可评估分析集客观缓解率。
主要发现
- 2017年12月19日至2019年6月19日入组剂量扩展组A组31例、B组13例、C组32例、D组27例。
- 主要终点中位随访:A组16.6个月(IQR 5.7-48.4),B组11.0个月(7.6-16.9),C组3.6个月(1.8-7.5),D组9.4个月(5.3-16.7)。
- A组27例可评估者中23例达客观缓解(85.2%;90% CI 69.2-94.8)。
- B组13例可评估者中8例达客观缓解(61.5%;90% CI 35.5-83.4),C组28例中7例(25.0%;12.4-41.9),D组27例中15例(55.6%;38.2-72.0),包括PIK3CA野生型和突变型肿瘤。
- 最常见3-4级治疗相关不良事件为中性粒细胞减少65/103(63%)、口腔炎28/103(27%)、皮疹21/103(20%);3-4级高血糖6/103(6%);治疗相关严重不良事件23/103(22%),无治疗相关死亡;9/103(9%)因治疗中出现的不良事件停药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PI3K-mTOR pathway is frequently dysregulated in breast cancer. Combining an inhibitor targeting all class I PI3K isoforms and mTOR complex 1 (mTORC1)-mTOR complex 2 (mTORC2) with endocrine therapy and a CDK4/6 inhibitor might provide more effective tumour control than standard-of-care therapy. To evaluate this hypothesis, gedatolisib, a pan-PI3K-mTOR inhibitor, was assessed in a phase 1b trial combined with palbociclib and endocrine therapy in patients with hormone receptor-positive, HER2-negative, advanced breast cancer. Results from the dose expansion portion of this trial are reported herein. METHODS: This multicentre, open-label, phase 1b study recruited female patients aged at least 18 years from 17 sites across the USA with hormone-receptor-positive, HER2-negative, advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-1. Four patient groups were studied in the dose expansion portion of the study: treatment-naive in the advanced setting (first line; group A), progression on 1-2 lines of endocrine therapy but CDK4/6 inhibitor-naive (group B); and one or more previous lines (second-line and higher) of therapy, including a CDK4/6 inhibitor (groups C and D). Gedatolisib 180 mg was administered intravenously weekly in 28-day treatment cycles for groups A-C, and on days 1, 8, and 15 for group D. Letrozole (group A), fulvestrant (groups B-D), and palbociclib (all groups) were administered at standard doses and schedules. The primary endpoint was investigator-assessed objective response rate per RECIST version 1.1 in the evaluable analysis set. This trial is completed and registered with ClinicalTrials.gov, NCT02684032. FINDINGS: Between Dec 19, 2017, and June 19, 2019, 103 female participants were enrolled in the dose expansion groups A (n=31), B (n=13), C (n=32), and D (n=27). Median follow-up was 16·6 months (IQR 5·7-48·4) for group A, 11·0 months (7·6-16·9) for group B, 3·6 months (1·8-7·5) for group C, and 9·4 months (5·3-16·7) for group D for the primary endpoint. Gedatolisib, palbociclib, and endocrine therapy induced an objective response in 23 (85·2%; 90% CI 69·2-94·8) of 27 evaluable first-line participants (group A). In the second-line and higher setting, an objective response was observed in eight (61·5%; 90% CI 35·5-83·4) of 13 evaluable group B participants, seven (25·0%; 12·4-41·9) of 28 evaluable group C participants, and 15 (55·6%; 38·2-72·0) of 27 evaluable group D participants; this included participants with both wild-type and mutated PIK3CA tumours. The most common grade 3-4 treatment-related adverse events were neutropenia (65 [63%] of 103), stomatitis (28 [27%]), and rash (21 [20%]). Grade 3-4 hyperglycaemia was reported in six (6%) participants. 23 (22%) of 103 participants had a treatment-related serious adverse event, and there were no treatment-related deaths. Nine (9%) participants discontinued treatment because of a treatment-emergent adverse event. INTERPRETATION: Gedatolisib plus palbociclib and endocrine therapy showed a promising objective response rate compared with the published results for standard-of-care therapies and had an acceptable safety profile. FUNDING: Pfizer and Celcuity.
引用
- Layman RM, Han HS, Rugo HS, et al. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024. PMID: 38547892. doi:10.1016/S1470-2045(24)00034-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。